| Not Yet Recruiting | A Phase I Platform Study of Target-Based Screened CAR-Macrophages for the Treatment of Advanced Malignant Tumo NCT07409766 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | EARLY_Phase 1 |
| Not Yet Recruiting | To Evaluate the Tolerability and Pharmacokinetics of TQB3142 for Injection in Patients With Advanced Malignant NCT07338838 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Recruiting | A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors NCT07038005 | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 1 |
| Recruiting | A Phase I Study of SSGJ-612 in Patients With Advanced Solid Tumors NCT07032298 | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 1 |
| Recruiting | A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors NCT07043751 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors NCT07016490 | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 1 |
| Recruiting | First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors NCT06877650 | Shanghai JMT-Bio Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors NCT06764771 | Bristol-Myers Squibb | Phase 1 |
| Not Yet Recruiting | JSKN033 in Chinese Subjects with Advanced Malignant Tumors NCT06770881 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 1 / Phase 2 |
| Not Yet Recruiting | AK137 (Bispecific Antibody Targeting CD73 and LAG-3) in Patients With Advanced Malignant Tumors NCT06691360 | Akeso | Phase 1 |
| Recruiting | A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors NCT06223841 | SUNHO（China）BioPharmaceutical CO., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Phase I Study of LNF1901 in Advanced Malignant Tumors NCT06226363 | Shandong New Time Pharmaceutical Co., LTD | Phase 1 |
| Active Not Recruiting | SG2918 For Advanced Malignant Tumors NCT06167486 | Hangzhou Sumgen Biotech Co., Ltd. | Phase 1 |
| Recruiting | A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors. NCT05877924 | NovaRock Biotherapeutics, Ltd | Phase 1 |
| Recruiting | A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors NCT05991583 | SUNHO（China）BioPharmaceutical CO., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 NCT05868876 | Akeso | Phase 1 |
| Recruiting | A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors NCT05779163 | Nanjing Leads Biolabs Co.,Ltd | Phase 1 / Phase 2 |
| Unknown | Dose Escalation and Expansion Study of SYH2043 in Patients With Advanced Malignant Tumors NCT05728541 | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | A Study of AK130 in Patients With Advanced Malignant Tumors NCT05653284 | Akeso | Phase 1 |
| Unknown | A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumor NCT05235542 | Akeso | Phase 1 / Phase 2 |
| Unknown | A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors NCT05396391 | SUNHO（China）BioPharmaceutical CO., Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors NCT05229497 | Akeso | Phase 1 / Phase 2 |
| Completed | Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant T NCT05223231 | Nanjing Leads Biolabs Co.,Ltd | Phase 1 / Phase 2 |
| Unknown | A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Pa NCT05198817 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 |
| Unknown | A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant Tumors NCT05193721 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 |
| Completed | A Study of AK112 in Advanced Malignant Tumors NCT05214482 | Akeso | Phase 1 / Phase 2 |
| Unknown | A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3617 Capsule in Patients With Advance NCT05110807 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Completed | A Phase Ib/II Clinical Study of LBL-007 in Combination With Toripalimab in Treatment of Advanced Malignant Tum NCT05102006 | Nanjing Leads Biolabs Co.,Ltd | Phase 1 / Phase 2 |
| Completed | Phase I Study of SHR-2002 + SHR-1316 in Patients With Advanced Malignant Tumors NCT05082545 | Atridia Pty Ltd. | Phase 1 |
| Unknown | Clinical Trial of IBC0966 in Patients With Advanced Malignant Tumors NCT04980690 | SUNHO（China）BioPharmaceutical CO., Ltd. | Phase 1 / Phase 2 |
| Unknown | Study of the Efficacy and Safety of IBI319 in Patients With Advanced Malignant Tumors NCT04708210 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Unknown | A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3804 in Subjects With Advanced Malignant Tumors NCT04128085 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Unknown | Study on the Correlation Between Immunoglobulin and Liposomal Doxorubicin in Vivo NCT05354076 | Fudan University | Phase 2 |